SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-121679
Filing Date
2024-11-06
Accepted
2024-11-05 18:16:09
Documents
76
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rare-20240930.htm   iXBRL 10-Q 2936561
2 EX-31.1 rare-ex31_1.htm EX-31.1 15875
3 EX-31.2 rare-ex31_2.htm EX-31.2 15351
4 EX-32.1 rare-ex32_1.htm EX-32.1 11715
5 GRAPHIC img216854513_0.jpg GRAPHIC 108100
  Complete submission text file 0000950170-24-121679.txt   10047829

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rare-20240930.xsd EX-101.SCH 1144766
79 EXTRACTED XBRL INSTANCE DOCUMENT rare-20240930_htm.xml XML 1755454
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36276 | Film No.: 241428784
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)